Mrs. Erony joined Signet Healthcare Partners in 2006 and has more than 20 years experience as a principal in investing activities, investment banking and business development. She is currently a Director of IGI Labs and Peak Surgical and has been a Director of Dow Pharmaceutical Sciences (acquired by Valeant), Atlantis Components (acquired by AstraZeneca) , and Control Delivery Systems (acquired by Psivida). Mrs. Erony is also a member of the Board of Directors of Orbis International, a non for profit organization dedicating to eliminating preventable blindness.

Previously, Mrs. Erony was a strategic advisor to Alcon Labs and was a Managing Director at Citigroup responsible for the Bank’s activities in specialty pharmaceuticals and medical technologies.

Mr. Gale is the founding partner of Signet Healthcare Partners. He initiates investments and provides active management oversight to a number of the portfolio companies. He is currently the Chairman of the Board of Alpex Pharma S.A., and also serves on the Board of Directors of Cedarburg Pharmaceuticals Inc., Cydex Inc., Indevus Pharmaceuticals, Inc., Spepharm BV and Paladin Laboratories.

Prior to founding Signet Healthcare Partners, Mr. Gale was head of principal investment activities and head of investment banking for Gruntal & Co., LLC. While at Gruntal, Mr. Gale’s investment activities included Andrx Corporation, Royce Laboratories (merged with Watson Pharmaceuticals), Lifecell Corporation, Neurocrine Biosciences, and BML Pharmaceuticals (acquired by Endo Pharmaceuticals).

Prior to joining Gruntal, he originated and managed private equity investments for the Home Insurance Co., Gruntal’s parent. Earlier in his career, Mr. Gale was a senior investment banker at E.F. Hutton & Co.

Mr. Gale received his Masters of Business Administration from the University of Chicago.

Mr. Hansen has been a Managing Director of Signet Healthcare Partners, since 2001. Mr. Hansen has over 20 years of private equity investment experience.

He was Chairman and interim CEO of Questcor Pharmaceuticals and currently serves as a Director of BioPro Pharmaceutical, Cedarburg Pharmaceuticals, LearnWright, and Malladi Drugs and Pharmaceuticals.

Mr. Hansen’s previous experience includes serving as a principal of Darby Overseas Investments Ltd., a private equity firm with a focus on emerging markets and as Director of Corporate Finance at the U.S. Treasury Department.

Early in his career, Mr. Hansen was an investment banker with Dillon Read & Co. Inc., focusing on mergers and acquisitions and an investment banker at E.F. Hutton & Co. Mr. Hansen also served in the U.S. Army as an Infantry and Special Forces officer.

Mr. Hansen has a B.A. from Princeton University and a Masters of Business Administration from the Wharton School, University of Pennsylvania.

Mr. Sone, Managing Director, of Signet was previously an Investment Director at Joddes Limited, an investment holding company with interests in a number of healthcare companies, including Pharmascience, Paladin Labs, Medicom, and Oral Science. He was the Director of Strategic Planning at Pharmascience Inc., one of the largest privately-owned generic pharmaceutical companies in the world.

Prior to joining Pharmascience, Mr. Sone was a large-cap pharmaceutical analyst at Morgan Stanley. He started his career at Mercer Management Consulting serving clients across North America in the transportation and healthcare industries.

Mr. Sone received a Bachelor of Commerce (with High Distinction) from the University of Toronto and an MBA from The Wharton School at the University of Pennsylvania.